Austin, Texas, August 12th, 2026, NewsDirect
- Earth Science Tech, a growing healthcare holding company, recently reported its Q1 2027 financial results, with key highlights including $9.0 million in revenue, $6.3 million in gross profit, $715,697 in net income, $707,131 in net cash, and $10.4 million in total assets.
- According to the CEO, the Q1 2027 figures reflect steady, compounding progress and are the result of a foundation built in the 2026 financial year.
- The company’s strategy of carefully acquiring and scaling cash-flowing assets across healthcare, pharmaceutical, and telemedicine sectors, is driving growth to support uplisting and attract institutional capital.
Earth Science Tech (OTC: ETST), a diversified holding company, recently announced its Q1 2027 financial results for the period ended June 30, 2026. Key financial highlights included increases in revenue, gross profit, net income, and total assets, compared to the same period in fiscal year 2026 (“Q1 2026”). According to Giorgio R. Saumat, CEO and Chairman of the Board, Q1 2027 underscored the durability of the foundation ETST established in fiscal 2026, with the results reflecting “steady compounding progress and the inherent operating leverage within its business model” (https://ibn.fm/p9BPV).
The company recorded $9.0 million in revenue in Q1 2027, up from $8.8 million in Q1 2026, representing a 3% growth. Its gross profit increased 3.1% to $6.3 million in Q1 2027 from $6.1 million in Q1 2026, while its net income jumped 57% to $715,697 from $456,714 over the intervening period. The company also reported a 108.4% increase in operating cash flow to…
NOTE TO INVESTORS: The latest news and updates relating to ETST are available in the company’s newsroom at https://ibn.fm/ETST
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
[email protected]
BioMedWire is powered by IBN
Contact
Editor
BioMedWire
BioMedWire
[email protected]